Bifidobacterium (mixed strains) are supported by a moderate level of scientific evidence for use in managing Inflammatory Bowel Disorders (IBD), including Crohn’s disease and ulcerative colitis. Numerous clinical studies and meta-analyses have investigated the efficacy of probiotics, including mixed Bifidobacterium strains, in IBD management. Evidence shows that certain combinations, such as those found in the formulation VSL#3 (which includes multiple Bifidobacterium strains alongside other probiotic species), can help induce and maintain remission in ulcerative colitis and may prevent pouchitis in post-surgical patients.

Several randomized controlled trials (RCTs) have demonstrated that Bifidobacterium-containing probiotics can modulate gut microbiota composition, enhance mucosal barrier function, and reduce markers of inflammation in IBD patients. A 2020 Cochrane review and other systematic reviews note benefits specifically for ulcerative colitis, though the data for Crohn’s disease are less robust and sometimes inconclusive. The strength of evidence is considered moderate, as results can vary depending on the strains used, the formulation, and patient populations. Safety profiles are generally favorable.

In summary, the use of mixed Bifidobacterium strains in IBD is justified by scientific research, especially as an adjunct to standard therapy in ulcerative colitis, but more high-quality, strain-specific trials are needed to solidify their role and determine optimal regimens.